Active early-stage investor Cherrystone Angel Group is a well-established angel network in New England and New York with a track record of over 25 million invested across 26 companies and participation in more than 80 funding rounds, signaling ongoing deal flow and a willingness to deploy capital in early-stage ventures.

Recent 2024 activity In 2024, members invested in three new companies including Flourish Care, Architect Health, and Clearlaw, indicating current deal activity and potential for follow-on rounds or co-investment opportunities with portfolio synergies.

Healthcare and MedTech focus Past investments such as Lenoss Medical and recent 2024 entries in Architect Health suggest a strong interest in health tech and biomedical ventures, presenting openings for partnerships, due diligence collaboration, or targeted deal sourcing in this sector.

Exits and value capture Notable exits like Medumo and Streamroot, plus a 2022 exit of a portfolio asset to TransACT, highlight the group’s capability to scale companies toward liquidity events, a selling point for portfolio optimization services and exit strategy advisory.

Operational readiness A lean team (11-50 employees) combined with a robust tech stack (Drupal, Squarespace, Microsoft 365) and a revenue range of 10–25 million positions Cherrystone as a scalable partner for AI-enabled scouting, portfolio management tools, and value-added services for growth-stage investments.